Press release
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development
Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. Dr. Yuxin Chen, with a strong academic background and solid capabilities in converting academic research into industrial applications, successfully led the global R&D and clinical development of multiple first-in-class (FIC) innovative drugs. The core products of ProteLight Pharmaceuticals, founded by Dr. Chen, have entered pivotal clinical trials in both China and the United States. They demonstrate outstanding original R&D capabilities and a forward-looking international development strategy. Dr. Chen was named a 2025 Forbes China Pioneer Innovator in Industry Development.
Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.,
[Honored as a 2025 Forbes China Pioneer Innovators in Industry Development]
Image: https://www.globalnewslines.com/uploads/2025/05/495282c2facd6379eb09fc3c07020f15.jpg
Dr. Wang Xin, Global Partner and President of Sullivan Greater China, together with Professor Yu Wang, Expert Advisor to the Judging Committee and Chairman of Chinese Foundation for Hepatitis Prevention and Control, presented the award to Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
China's Pioneer in Antimicrobial Peptide Innovation: ProteLight Pharma's Peceleganan Ushers in a New Era of Anti-Infective Therapy
ProteLight Pharma has achieved a historic breakthrough in China's innovative drug development with its independently developed antimicrobial peptide spray Peceleganan (PL-5). It is the first antimicrobial peptide innovative drug in China to enter clinical trials and submit a New Drug Application (NDA), and it has also advanced to Phase II clinical trials in the United States. In addition, it has been granted the WHO International Nonproprietary Name (INN) "Peceleganan," marking the first time a Chinese-developed antimicrobial peptide compound has obtained an international nonproprietary name. Dr. Yuxin Chen, founder of ProteLight Pharma, proposed the revolutionary "Membrane Discrimination Mechanism," which fundamentally addresses the problem of antimicrobial resistance. In clinical trials, the Peceleganan spray demonstrated broad-spectrum efficacy, high potency, and a low potential for resistance. This breakthrough innovation received the "Peptide Application Special Award" at the 15th Chinese International Peptide Symposium. Based on this original mechanism, ProteLight Pharma has established a world-leading rational design platform for antimicrobial peptide drug development, along with an advanced formulation R&D platform for peptide drugs, laying a solid foundation for the future growth of its product pipelines.
A Full Value Chain Creator: An Outstanding Model of R&D Breakthroughs and Commercialization
ProteLight Pharma has signed an exclusive cooperation agreement with China's pharmaceutical giant Chia Tai Tianqing, which is responsible for the full-scale commercialization of the PL-5 spray in the Chinese market. The company is now valued at over 2 billion RMB and has secured more than 60 million RMB in funding from the national "12th Five-Year Plan" and "13th Five-Year Plan" Major New Drug Innovation Programs, as well as from provincial and municipal science and technology funds. Notably, PL-5 has demonstrated significantly better clinical efficacy than traditional antibiotics in treating difficult-to-heal infected wounds such as diabetic foot ulcers and extensive burns. It has consistently met primary endpoints across all phases of clinical trials, providing a Chinese solution to the global problem of drug-resistant bacterial infections. In addition to anti-infective therapies, ProteLight Pharma is also expanding into oncology, autoimmune diseases, and metabolic disorders. The company has already developed several preclinical-stage innovative drug candidates in these areas.
China's Strength in the Global Battle Against Antimicrobial Resistant Bacteria: Building a Sustainable Biopharmaceutical Innovation Engine
Facing the growing global crisis of antibiotic resistance, ProteLight Pharma is seizing the historic opportunity for antimicrobial peptide drug development and has laid out a clear development plan. Peceleganan is expected to obtain its new drug certificate in early 2026, and the follow-up product PL-18 is scheduled to enter Phase III clinical trials in China in the fourth quarter of 2025. The company is currently advancing its Round E financing, with a focus on strengthening its R&D system and expanding its product pipeline. Dr. Yuxin Chen emphasized that ProteLight Pharma will remain committed to continuous innovation based on its original technology platform. Through further development and application of the "Membrane Discrimination Mechanism," the company aims to systematically address key technical challenges from drug discovery to industrialization. Committed to tackling global public health challenges, ProteLight Pharma strives to become a global leader in the field of antimicrobial peptides. This strategic positioning reflects the company's strong sense of social responsibility and highlights the ambition and strength of Chinese innovative pharmaceutical companies in global health governance.
About Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd.
Founded in April 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. is a high-tech biopharmaceutical company focused on the research, development, and production of peptide and small-molecule drugs. The company is based in Jiangyin Hi-Tech Industrial Development Zone, Jiangsu Province, and is recognized as a National High Tech Enterprise. ProteLight Pharma has several subsidiaries, including wholly owned R&D subsidiaries Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. and Nanjing Denovo Pharmaceutical Technology Co., Ltd., as well as Jiangsu Putai Pharmaceutical Technology Co., Ltd., ProteLight Medical Holdings (Hong Kong) Co., Ltd., and ProteLight Pharma (Australia) Pty Ltd.
Innovation-driven drug R&D and production is the core strategy of the company. It has built a diversified pipeline of first-in-class peptide and small-molecule innovative drugs, with a focus on anti-infective, oncology, autoimmune, and metabolic diseases. The company holds dozens of patents, including PCT international patents, U.S. and EU patents, Chinese invention patents, utility model patents, and design patents.
Since its founding, ProteLight Pharma has undertaken over 40 scientific research projects, including the national "Major New Drug Innovation" projects under the 12th and 13th Five-Year Plans, and the "Funding Program for Preferential Returned Scientific Research Students Innovative and Start-ups."
The company was selected as one of the first key entrepreneurial teams by the Overseas Chinese Affairs Office and was awarded the "Outstanding Entrepreneur Award".
Looking ahead, the company will continue to build on its antimicrobial peptide product foundation, maintaining a balanced focus on R&D and business operations. With high-quality innovative products, ProteLight Pharma aims to become a global leader in the field of antimicrobial peptide pharmaceuticals.
About the 2025 Forbes China Pioneer Innovators in Industry Development Selection
The "2025 Forbes China Pioneer Innovators in Industry Development" selection is jointly organized by Forbes China and Frost & Sullivan. It aims to identify and recognize entrepreneurs who demonstrate innovation and leadership in key areas such as life sciences, industry and energy, AI and information technology, and consumer finance and services. The evaluation process adopts rigorous data analysis and case study methodologies to comprehensively assess candidates' innovation strategies, market influence, and growth potential. This selection not only serves as an authoritative recognition of industry leaders, but also aims to inspire more entrepreneurs to embrace technological innovation and contribute to the sustainable development of their industries.
Media Contact
Company Name: Frost & Sullivan
Contact Person: Qian Li
Email: Send Email [http://www.universalpressrelease.com/?pr=dr-yuxin-chen-president-and-ceo-of-jiangsu-protelight-pharmaceutical-biotechnology-co-ltd-honored-as-a-2025-forbes-china-pioneer-innovators-in-industry-development]
Country: China
Website: http://www.frostchina.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dr. Yuxin Chen, President and CEO of Jiangsu ProteLight Pharmaceutical & Biotechnology Co. Ltd., Honored as a 2025 Forbes China Pioneer Innovators in Industry Development here
News-ID: 4009178 • Views: …
More Releases from Getnews
gardenLAB Expands Thoughtful Landscape Design Services in Dallas, TX
Image: https://www.globalnewslines.com/uploads/2026/02/1771523043.jpg
gardenLAB, a Dallas-based landscape design studio, continues to shape resilient and design-forward outdoor spaces across North Texas. Known for a refined, site-responsive approach, gardenLAB delivers landscapes that balance aesthetics, function, and long-term adaptability to the regional climate.
February 20, 2026 - Dallas, TX - With a focus on integrated planning and horticultural expertise, gardenLAB supports residential and commercial properties through services aligned with Groundskeeping Dallas [https://www.gardenlab.design/services#:~:text=GARDENING%20%26%20SEASONAL%20COLOR] standards, ensuring landscapes remain…
Let Kids Be Kids, Arshiner's 2026 Spring/Summer Collection Brings Festive Joy in …
In 2026, American parents' approach to choosing children's clothing is undergoing a quiet transformation. Instead of focusing on outfits for specific festive occasions to create a sense of ritual, they are now embracing real-life daily scenarios. During those moments of running, exploring, laughing, and growing, clothing should be an extension of joy and freedom. At the heart of this trend is the idea that children should not only shine on…
"One Outfit, Multiple Wears" Becomes a New Travel Trend: EKOUAER Travel Homewear …
From an overstuffed suitcase that's hard to zip up, to tight outfits on the plane that make it difficult to breathe, to the moment when you check into a hotel and want to go out for a cup of coffee but can't find a comfortable and appropriate outfit... At such times, we often lament: A truly enjoyable journey really requires a set of homewear that can "go wherever you go."…
HowtoAchieveBothSafetyandComfortinSpringandSummerClose-to-SkinOutfits, COOFANDYO …
Image: https://www.globalnewslines.com/uploads/2026/02/14ee3a9cbf6b505268b80216af836535.jpg
As temperatures gradually warm, spring and summer styling has become a focus in men's daily dressing. Compared to autumn and winter, spring and summer clothing is lighter, thinner, and more close-fitting, with longer and more extensive contact with the skin. This shift has led people to pay greater attention to the safety, comfort, and breathability of clothing materials. When garments almost become a "second skin," factors such as skin-friendliness,…
More Releases for ProteLight
Diabetic Foot Ulcer Treatment Pipeline Shows Strong Momentum as 20+ Pharma Compa …
DelveInsight's, "Diabetic Foot Ulcer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Foot Ulcer pipeline landscape. It covers the Diabetic Foot Ulcer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Foot Ulcer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive…
Diabetic Foot Ulcers Pipeline Insight 2025: 25+ Regenerative, Antimicrobial, and …
DelveInsight's "Diabetic Foot Ulcers - Pipeline Insight, 2025" survey examines more than 25 therapies in development that address diabetic foot ulcers (DFUs), a leading cause of morbidity and lower-limb amputation in individuals with diabetes. Despite improvements in wound care protocols, offloading, and revascularization techniques, many patients experience chronic, non-healing wounds that drive hospitalizations, healthcare costs, and poor quality of life-highlighting substantial unmet clinical need.
The DFU pipeline is rapidly diversifying across…
Diabetic Foot Ulcers Pipeline: Leading Innovation with 20+ Groundbreaking Therap …
The Diabetic Foot Ulcers market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Cell2Cure ApS, Lakewood-Amedex, and FibroBiologics. These industry pioneers are transforming treatment strategies and redefining the future of Diabetic Foot Ulcers, bringing new hope to patients worldwide.
DelveInsight's "Diabetic Foot Ulcers Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Diabetic Foot Ulcers market. The report…
Breath Freshener Spray Market Strategic Insights Of Developing Industry Growing …
The latest research on Breath Freshener Spray Market provides a thorough examination of the most current developments in the Breath Freshener Spray and the key dynamics that are driving growth. It is a research report that examines market drivers, restraints, challenges, risks, and development prospects in the global market for Breath Freshener Spray. The global Breath Freshener Spray market report is a systematic study of the Breath Freshener Spray industry,…
Antimicrobial Peptides Market Growth, Competitive Analysis and Forecast 2027| An …
The global Antimicrobial Peptides market size is expected to reach US$ 6 million by the end of 2027, with a CAGR of 5.4% during 2021-2027. Antimicrobial peptides (AMPs), also called host defence peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which…
Plant Antimicrobial Peptides Market global outlook and forecast 2021 -2027| Prot …
The Global Plant Antimicrobial Peptides Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Plant Antimicrobial Peptides makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise spins around the…
